Related Experiment Video
Updated: Dec 13, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
Exploring payments in the US pharmaceutical market from 2011 to 2019: Update on pharmacy benefit manager impact
Emery P Weinstein1, Kevin Schulman1
1Department of Health Policy and Management, Mailman School of Public Health, Columbia University (EPW), New York City, NY; Clinical Excellence Research Center, Department of Medicine (KAS), and the Graduate School of Business (KAS), Stanford University, Stanford, CA.
Abstract:
We extended an earlier analysis of the gross revenue, payments, and net revenues of pharmaceutical manufacturers to include data from 2017 through 2019. In the period of 2017 to 2019, we found that gross revenue increased by 6.8% per annum, and payments from manufacturers increased by 13.5% annually, whereas net revenues for the same manufacturers increased by only 2.9% annually. By 2019, these same firms made payments of 67.4% of net revenue, or $141.4 billion, to generate $209.9 billion in net sales. We observed that list price increases and payments have been growing disproportionally to manufacturer net income despite widespread public concern about rising outpatient prescription drug prices.
More Related Videos
10:17A Mass Spectrometry-Based Approach to Identify Phosphoprotein Phosphatases and their Interactors
Published on: April 29, 2022
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Control Governance: Regulatory Bodies and Their Impact
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
FDA Approved Drugs: Changes to Approved Drugs
Measurement of Bioavailability: Pharmacodynamic Methods
Biopharmaceutics and Pharmacokinetics: Overview